Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply
Lancet Oncol
.
2020 May;21(5):e234.
doi: 10.1016/S1470-2045(20)30237-0.
Authors
Robert H Jones
1
,
Angela Casbard
2
,
Margherita Carucci
2
,
Andrew Foxley
3
,
Sacha J Howell
4
Affiliations
1
Velindre Cancer Centre, Cardiff, UK. Electronic address:
[email protected]
.
2
Centre for Trials Research, Cardiff University, Cardiff, UK.
3
Oncology R&D, AstraZeneca, Cambridge, UK.
4
Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
PMID:
32359499
DOI:
10.1016/S1470-2045(20)30237-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Aromatase Inhibitors
Aromatase*
Estrogens
Fulvestrant*
Humans
Neoplasm Recurrence, Local
Substances
Aromatase Inhibitors
Estrogens
Fulvestrant
Aromatase